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Ab stra ct
The es sen tial ele men ts of a qua li ty prog ram, spe ci 0  cal ly in ter nal qua li ty con trol (IQC) and exter nal qua li ty as su ran ce (EQA), shou ld be ap plied to ea-
ch la bo ra to ry as say per for med in or der to en su re te st re su lt ac cu ra cy and pre ci sion. The coa gu la tion la bo ra to ry plays an im por ta nt ro le in the diag-
no sis and treat me nt of in di vi dua ls wi th blee di ng or clot ti ng (i.e., throm bo tic) di sor de rs. Te st met ho do lo gies used to as se ss com mon di sor de rs or di-
sea ses of hae mos ta sis are re viewed as we ll as the cli ni cal re le van ce of ea ch as say. The prea na lyti cal pha se of tes ti ng o8 e rs the grea te st op por tu ni ty 
for in tro du ci ng re su lt er ror in the hae mos ta sis la bo ra to ry and it is the re fo re im pe ra ti ve that sam ples are pro per ly co llec ted, tran spor ted and sto red. 
Samples for hae mos ta sis tes ti ng shou ld be col lec ted in 3.2% so dium cit ra te at a 9:1 blood to an ti coa gu la nt ra tio and main tai ned at room tem pe ra tu-
re un til pro ces sed. So me te st pro ces ses su ch as pla te let fun ction tes ti ng ha ve spe cial pro ces si ng and tes ti ng require men ts. For plas ma-ba sed tes ts, 
cen tri fu ga tion to ob tain pla te let poor plas ma and tes ti ng shou ld ideal ly be com ple ted wit hin 4 hou rs or the plas ma fro zen. IQC mu st be per for med 
wi th ea ch as say, at ap prop ria te le ve ls of the ana lyte and at ap prop ria te time in ter va ls as a mea ns for as ses si ng on goi ng as say per for man ce. EQA, a 
peer group as ses sme nt pro ce ss that is sup ple men ta ry to IQC, o8 e rs in ad di tion the op por tu ni ty for eva lua tion of lo ng-te rm per for man ce of la bo ra-
to ries, in clu di ng com pa ri so ns wi th li ke and un li ke met ho do lo gies, and of ten ser ves as an edu ca tio nal re sour ce. Par ti ci pa tion in an EQA prog ram is 
of ten a requi re me nt of la bo ra to ry ac cre di ta tion and the re are a mul ti tu de of EQA or ga ni za tio ns that o8 er prog ra ms spe ci 0 c to hae mos ta sis tes ti ng 
with in ter na tio nal prog ra ms pro vi di ng as ses sme nt of the mo re spe cia li zed hae mos ta sis as says. The se prog ra ms pro vi de in va luab le in for ma tion on 
as say spe ci 0 c diag nos tic er ror ra te, as say pre ci sion, ac cu ra cy, sen si ti vi ty and as ses sme nt of ove ra ll as say per for mance. The in cor po ra tion of IQC and 
EQA in to a la bo ra to ry prog ram can not on ly as si st in the as su ran ce that tes ti ng is re liab le and ac cu ra te but al so im pro ve the qua li ty of the tes ti ng.
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In tro duc tion
“Do the rig ht thin g” and “Do the thi ng rig ht” (to 
bor row from so me col lea gues (1)), are two sim ple 
sta te men ts that iden ti fy the fun da men tal as pec ts 
of what ‘qua li ty’ shou ld rep re se nt to us. One par ti-
cu lar pub li ca tion (2) from the Cli ni cal La bo ra to ry 
Stan dar ds In sti tu te (CLSI) (pre vious ly known as the 
Na tio nal Com mit tee for Cli ni cal La bo ra to ry Stan-
dar ds (NCCLS)) iden ti X es se ve ral ma jor ac ti vi ties of 
im por tan ce to a la bo ra to ry qua li ty prog ram, in clu-
di ng per son nel develop me nt, equip me nt choi ce 
and ope ra tion, pro ce ss im pro ve me nt, and sa fe ty. 
Al so lis ted are two ot her es sen tial ele men ts that 
are the pri ma ry fo cus of the cur re nt re po rt, na me-
ly in ter nal qua li ty con trol (IQC) and exter nal qua li-
ty as su ran ce (EQA) for in di vidual te st pro ces ses. In 
ad di tion to IQC and EQA, the cur re nt re po rt al so 
brieZ y men tio ns extra-a na lyti cal is sues and reZ ec-
ts on so me key gui de li nes avai lab le from va rious 
expe rt bo dies to en su re per for man ce of op ti mal 
tes ti ng wit hin the X e ld of hae mos tasis. The de ve-
lop me nt of the se cri ti cal ele men ts hel ps to en su re 
that the da ta re por ted by the la bo ra to ry are as ac-
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cu ra te as pos sib le and that they be st ser ve the 
nee ds of bo th pa tien ts and cli ni cia ns (3–7).
Over view of coa gu la tion and 
hae mos ta sis
Hae mos tasis, in vi vo, is the ho meos ta tic pro ce ss 
whe re by blood Z ow is main tai ned wit hin the vas-
cu la tu re and, in vit ro, rep re sen ts one of the mo st 
com plex areas of diag nos tic la bo ra to ry tes ti ng (8). 
The main fun ction of hae mos ta sis, to main tain 
blood Z ow in the inta ct ves se ls in nor mal cir cu la-
tion, is in pa rt ac hie ved by e_ or ts to ar re st blood 
lo ss re sul ti ng from inju ry or trau ma. The re are 
three main pha ses of hae mos ta sis, the vas cu lar 
pha se (whi ch in cor po ra tes pla te let in te rac tion), 
the coa gu la tion pha se (which in vol ves coa gu la tion 
pro tei ns and phos pho li pid com plexes), and the 
na tu ral an ti coa gu la nt/fibrinolytic pha se (whi ch 
en su res ces sa tion of the clot ti ng pro ce ss, the dis-
so lu tion of the throm bo sis, and per mi ts la ter wou-
nd hea li ng). The se com po nen ts wo rk in conce rt. 
When any pha se of this pro ce ss is dis tur bed, ad-
ver se cli ni cal even ts may oc cur, ma ni fes ti ng as eit-
her throm bo sis (ha e mos ta sis pus hed in a pro coa-
gu la nt di rec tion) or blee di ng (ine_ ec ti ve hae mos-
ta sis). In eit her si tua tion, the cli ni cian mu st ha ve 
access to a va rie ty of re le va nt tes ts in or der to ac-
hie ve a spe ci X c or cor re ct diag no sis and ini tia te 
ap prop ria te pa tie nt treat me nt or ma na ge me nt.
Wor ke rs wit hin hae mos ta sis of ten re fer to the abo-
ve syste ms in ter ms of ‘pri ma ry’ and ‘se con da ry’ 
hae mos ta sis, both of whi ch pro mo te even tual clot 
for ma tion. Pri ma ry hae mos ta sis re fe rs to the pro-
ce ss that in vol ves pla te le ts ad he ri ng to ea ch ot her 
and to the da ma ged vas cu la tu re sub seque nt to 
the ini tia ti ng eve nt (e.g., tis sue inju ry), fol lowed by 
pla te let ac ti va tion and ag gre ga tion to pro du ce a 
‘pla te le t-plug’. Se con da ry hae mos ta sis in vol ves 
the ac ti va tion of the clot ti ng system in a com plex 
in te rac ti ve fas hion wi th po si ti ve and ne ga ti ve 
feed ba ck, that cau ses sequen tial ac ti va tion of mul-
tip le coa gu la tion fac to rs and the even tual con ver-
sion of ‘so lub le’ X b ri no gen (the main clot tab le 
pro tein in plas ma) to ‘in so lub le’ X b rin. The pro ce ss 
of se con da ry hae mos ta sis in pa rt ac ts to stren-
gthen the pla te let plug, for mi ng a ge l-li ke clot. 
This pro ce ss is ke pt in che ck, in pa rt, by the na tu-
ral ly oc cur ri ng an ti coa gu la nt system, e.g., pro tein 
C (PC), pro tein S (PS), antit hrom bin (AT). The X b ri-
no lytic system rep re sen ts a dis tin ct, but in te r-re la-
ted pro ce ss that is in vol ved in lysis of the clot to 
fa ci li ta te wou nd hea li ng.
Com mon disor de rs and di sea ses of 
hae mos ta sis
Ma ny cli ni cal ly re le va nt di sea se pro ces ses can be 
de X  ned by a pro ce ss of ‘aber ra nt’ hae mos ta sis, 
and so me of the mo st im por ta nt in clu de hae mop-
hi lia, von Wil leb ra nd di sea se (VWD) and a va rie ty 
of throm bop hi lic di sor de rs, cau si ng eit her ar te rial 
or ve nous throm bo sis. The se di sor de rs of hae mos-
ta sis can be eit her in he ri ted (i.e., con ge ni tal or ge-
ne tic de fe ct) or acqui red (i.e., se con da ry to so me 
ot her di sea se). In or der to screen, diag no se and 
mo ni tor the se di sor de rs, the mode rn hae mos ta sis 
la bo ra to ry mu st be equip ped wi th an ar se nal of 
tes ts to al low ac cu ra te and com ple te diag no ses.
Blee di ng di sor de rs
Hae mop hi lia is cau sed by a de X  cien cy of usual ly 
one and ra re ly se ve ral clot ti ng fac to rs, whi ch may 
ari se con ge ni tal ly or may be acqui red. Hae mop hi-
lia A is the mo st com mon fo rm (9) and is at tri bu-
tab le to a de X  cien cy or de fe ct in fac tor VIII (FVIII). 
Hae mop hi lia B is le ss com mon and at tri bu tab le to 
a de X  cien cy or de fe ct in fac tor IX (FIX; al so cal led 
Chris tmas fac tor). As both FVIII and FIX are es sen-
tial for the pro ce ss of se con da ry hae mos ta sis, de X -
cien cies of eit her are as so cia ted wi th a blee di ng 
diat he sis. Hae mop hi lia A is ap proxi ma te ly se ven ti-
mes mo re com mon than Hae mop hi lia B. As con-
ge ni tal di sor de rs, bo th reZ e ct sex-linked re ces si ve 
di sor de rs as the de fec ti ve ge nes are car ried on the 
X chro mo so me. The deg ree of the fac tor de X  cien-
cy can va ry from a com ple te de X  cien cy to upwar-
ds of arou nd 40% of nor mal, wi th in crea si ng blee-
di ng se ve ri ty as so cia ted to lower le ve ls of functio-
nal clot ti ng fac to rs.
VWD is anot her blee di ng di sor der that ari ses from 
de X  cien cies or de fec ts in the plas ma pro tein von 
Wil leb ra nd fac tor (VWF) (10). It usual ly pre sen ts wi-
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th mi ld blee di ng ten den cies su ch as epi ta sis and 
ea sy brui si ng and mo st of ten has a con ge ni tal na-
tu re but may al ter na ti ve ly be acqui red. VWF is sto-
red pri ma ri ly in the pla te le ts and en dot he lial cel ls 
and has two main fun ctio ns wit hin hae mos ta sis 
(8). Fir stly, VWF me dia tes the for ma tion of the pla-
te let hae mos ta tic plug by ac ti ng as the main ad-
he si ve pro tein that brid ges pla te le ts to the da ma-
ged vas cu la tu re as we ll as to ot her pla te le ts. Se-
con dly, VWF ac ts as a pro tec ti ve car rier pro tein for 
FVIII in plas ma, pre ven ti ng its pre ma tu re deg ra da-
tion. VWF fun ctio ns in this man ner by mea ns of 
spe ci X c in te rac tio ns wi th extra cel lu lar mat rix com-
po nen ts su ch as col la gen, spe ci X c in te rac tio ns wi-
th va rious pla te let re cep to rs, and a speciX c in te-
rac tion wi th FVIII (8,10). VWF is thus es sen tial for 
bo th the ini tial tet he ri ng of pla te le ts to the dam-
aged vas cu la tu re (i.e., pri ma ry hae mos ta sis), as we-
ll as the even tual X b rin clot for ma tion (i.e., se con-
da ry hae mos ta sis), be cau se it as sem bles wi th the 
pro coa gu la nt FVIII in plas ma, for mi ng a pro tec ti ve 
com plex that pre ven ts its ra pid clea ran ce in cir-
culation. In plas ma, VWF com pri ses a se ries of di-
mer pro tei ns of in crea si ng si ze (or mo le cu lar weig-
ht); the lar ger the si ze (or mo le cu lar weig ht), the 
mo re ad he si ve the mo le cu le. De fec ts in VWD may 
com pri se lo ss of all for ms of the VWF pro tein (i.e., 
quan ti tative de fec ts; de X  ni ng Type 1 or 3 VWD) or 
se lec ti ve lo ss of on ly the hi gh mo le cu lar weig ht 
(HMW) for ms or ot her se lec ti ve qua li ta ti ve de fec ts 
(i.e., de X  ni ng Type 2 VWD).
A ho st of pla te let de fec ts can al so lead to mu co cu-
ta neous blee di ng or brui si ng (11–14). Pla te le ts con-
sti tu te a sto re-hou se of hae mos ta sis, in clu di ng 
sur fa ce glycop ro tein re cep to rs and al pha and be ta 
gra nu le com po nen ts. In or der for pla te le ts to exe rt 
their im por ta nt ro le in hae mos ta sis, the se re cep to-
rs need to fun ction, and the gra nu le conten ts 
need to be nor mal and re lea sed in to the sur roun-
di ng mi lieu. Pla te let de fec ts as so cia ted wi th blee-
di ng of ten rep re se nt de fec ts of de X  cien cies of pla-
te let glycop ro tei ns, sec re tion di sor de rs, sto ra ge 
po ol di sor de rs, and sig nal tran sduc tion di sor de rs.
Throm bo tic di sor de rs
Throm bop hi lia can be de X  ned as an in crea sed ri sk 
of throm bo sis and can be he re di ta ry or acqui red. 
La bo ra to ry tes ti ng of throm bop hi lia requi res a pa-
nel of te st pro ce du res that can be mo le cu la r-ba-
sed, fun ctio nal or an ti ge nic in na tu re. A wi de va-
rie ty of di sor de rs can gi ve ri se to a throm bop hi lic 
ten den cy, in clu di ng de X  cien cies or de fec ts in the 
na tu ral an ti coa gu la nt pro tei ns (i.e., AT, PC, PS), in-
crea ses in pro coa gu la nt pro teins or im pai red X b ri-
no lysis (8,15–17). Thus, whil st a la ck of pro coa gu la-
nt pro tei ns in clu di ng FVIII and VWF may cau se 
blee di ng, an exce ss of the se may cau se throm bo-
sis. Acqui red pre dis po si tion to throm bo sis can al so 
oc cur in ma ny di sea se sta tes, and one of the mo st 
im por ta nt and com mon is the au to-im mu ne di sor-
der called the antip hos pho li pid anti bo dy syndro-
me (APS), whi ch ari ses due to the pre sen ce of an-
tip hos pho li pid an ti bo dies (a PL), de tec tab le in the 
la bo ra to ry usi ng a va rie ty of tes ts in clu di ng tho se 
for Lu pus An ti coa gu la nt (LA), an ti car dio li pin an ti-
bo dy (a CL) and an ti-Be ta2-glycop rotei n-I (aB2GPI) 
an ti bo dies (18,19).
Tes ts and as says wit hin hae mos ta sis
The mo de rn hae mos ta sis la bo ra to ry per for ms an 
ar se nal of tes ts to al low an ac cu ra te and com pre-
hen si ve diag no sis of hae mos ta tic de fec ts. So me 
tes ts are al so used to mo ni tor an ti coa gu la nt the ra-
py. It is con ve nie nt to se pa ra te the se tes ts in to 
‘rou ti ne coa gu la tion tes ts’, whi ch are typi cal ly hi gh 
throug hput scree ni ng tes ts per for med by mo st 
cli ni cal la bo ra to ries, and ‘diag nos tic hae mos ta sis 
as says’. Al so com mon ly ca lled ‘spe cial coa gu la tion’ 
tes ts, the se lat ter as says are typi cal ly lower throu-
gh-put and per for med by spe cia li zed hae mos ta sis 
la bo ra to ries for the spe ci X c diag no sis and cha rac-
te ri za tion of hae mos ta tic di sea ses and de fec ts.
Rou ti ne coa gu la tion tes ts
Prot hrom bin time (PT)
First pro po sed by Qui ck in 1935 (20), the PT is per-
ha ps the ol de st te st of coa gu la tion sti ll per for med. 
The PT is a mea su re of the fun ction of the tis sue 
fac tor pat hway (al so so me ti mes cal led the ‘extrin-
sic pat hway’). The te st is per for med by ad di ng tis-
sue fac tor and phos pho li pi ds to plas ma and then 
mea su ri ng the ti me in se con ds to clot for ma tion 
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fol lowi ng the ad di tion of cal cium. The PT is an in 
vit ro te st that ba si cal ly mi mi cs the in vi vo eve nt of 
da ma ged tis sue extrac ts ac ti ng on the coagula-
tion system to ini tia te the clot ti ng pro ce ss. Ori gi-
nal ly de ve lo ped to mea su re prot hrom bin (one of 
the pro coa gu la nt fac to rs and hen ce its na me), the 
PT is al so now known to mea su re ot her as pec ts of 
the coa gu la tion pat hway su ch as the in te rac tion of 
FV, FVII, FX and the con cen tra tion and fun ction of 
X b ri no gen.
In ter na tio nal Nor ma li zed Ra tio (INR)
This is sim ply a mat he ma ti cal pro ces si ng of the PT 
that per mi ts stan dar di za tion of te st re sul ts ac ro ss 
di_ e re nt la bo ra to ries, and is cal cu la ted by mea ns 
of two ad di tio nal com po nen ts cal led the In ter na-
tio nal Sen si ti vi ty In dex (ISI) and the Mean No rmal 
Prot hrom bin Ti me (MNPT) (21,22). The INR is used 
in ter na tio nal ly for the mo ni to ri ng of vi ta min K an-
ta go ni st (VKA) the ra py (e.g., War fa rin), of ten gi ven 
to in di vi duals as a ma na ge me nt the ra py for throm-
bo sis.
Ac ti va ted par tial throm bop las tin ti me (APTT)
This te st scree ns for ab nor ma li ties of the ‘con ta ct-
fac tor’ (so me ti mes al so cal led the ‘in trin sic’) pat-
hway (i.e., de X  cien cies or de fec ts in FVIII, FIX, FXI, 
and FXII), as we ll as the com mon pat hway (i.e., X b-
ri no gen, FII, FV, FX). The APTT is al so used for mo-
ni to ri ng of he pa rin the ra py and is va rious ly sen si ti-
ve to se ve ral in hi bi to rs in clu di ng LA (23). In all the 
abo ve ca ses, one expec ts to see a pro lon ga tion in 
the APTT. In con tra st, a shor te ned APTT is as so cia-
ted wi th an in crea sed throm bo sis ri sk (23–25). The 
ac ti va tor in this te st can be from se ve ral sour ces. 
Ori gi nal ly kao lin was used (hen ce, the te st was 
pre vious ly cal led PTTK) but in mo re re ce nt ti mes 
ac ti va tors su ch as mic ro ni zed si li ca and el la gic acid 
ha ve been sub sti tu ted. The APTT is the ti me to clot 
in se con ds when con ta ct ac ti va tor and phos pho li-
pi ds are ad ded to plas ma in the pre sen ce of cal-
cium.
Throm bin time (TT)
This is a sim ple te st per for med by adding equal 
vo lu mes of plas ma and throm bin and mea su ri ng 
the amou nt of ti me un til a clot for ms. The TT is 
sen si ti ve to he pa rin, di re ct throm bin in hi bi to rs 
and to de fec ts and de fi cien cies of fib ri no gen. 
Thus, a pro lon ged TT wi ll oc cur wi th con ge ni tal 
ab no rmali ties su ch as afib ri no ge nae mia and 
dysX b ri no ge nae mia as we ll as wi th the pre sen ce 
of in hi bi to ry sub stan ces in clu di ng he pa rin or hi-
gh le ve ls of X b ri n(o gen) deg ra da tion pro duc ts 
(FDPs).
Fib ri no gen
This rep re sen ts the ma jor clot tab le pro tein wit hin 
pla sma, and was ori gi nal ly mea su red by heat pre-
ci pi ta tion. The se days, X b ri no gen is mea su red im-
mu no lo gi cal ly or mo re com mon ly usi ng a fun ctio-
nal von Clau ss as say, whi ch can be ea si ly au to ma-
ted. Fib ri no gen le ve ls can al so be es ti ma ted usi ng 
a de ri ved cal cu la tion from the PT wi th se lec ti ve in-
stru men ta tion. The mea su re me nt of X b ri no gen is 
im por ta nt wit hin the con text of po ten tial con ge ni-
tal ab nor ma li ties su ch as aX b ri no ge nae mia and 
dysX b ri no ge nae mia (per ha ps stran ge ly, the se may 
be as so cia ted wi th bo th blee ding and throm bo sis) 
(26,27), as we ll as in the con text of trau ma, sna ke 
bi te, and disse mi na ted intra vas cu lar coa gu la tion 
(DIC) (28).
D-di mer
This rep re sen ts a spe ci X c break down frag me nt of 
X b rin, and so is a mea su re of X b ri no lysis. This te st 
is im por ta nt in or der to as se ss the pos si bi li ty of 
clot dis so lu tion as a mar ker of throm bosis; e.g., 
deep vein throm bo sis (DVT) or pul mo na ry embo li-
sm (PE) or aber ra nt clot ac ti va tion pro ces ses su ch 
as DIC (28–30).
Diag nos tic hae mos ta sis assays
Fac tor as says
The se are per for med by mo di X  ca tio ns of PT or 
APTT as says, usi ng se ve ral plas ma di lu tio ns, in or-
der to pin poi nt spe ci X c fac tor de X  cien cies (e.g., 
FVIII or FIX in clas si cal hae mop hi lia). Tes ts are ma-
de in di vi dual ly spe ci X c for any gi ven fac tor by 
usi ng the parti cu lar fac tor de X  cie nt plas ma. The 
excep tion he re is FXIII, or the X b rin sta bi li si ng fac-
tor, whi ch is mea su red usi ng al ter na te tec hniques 
(31).




The se com pri se a pa nel of tes ts, pri ma ri ly to he lp 
eva lua te for a blee di ng di sor der su ch as VWD (32), 
al thou gh VWF is al so bei ng in crea sin gly reques ted 
wit hin the con text of throm bo tic di sea se (16). So-
me as says mea su re the quan ti ty of VWF pre se nt in 
plas ma (i.e., VWF an ti gen (VWF:A g)), re gar dle ss of 
the pre sen ti ng qua li ty (or VWF fun ction). Ot her as-
says mea su re fun ctio nal pro per ties of VWF; the se 
in clu de the ris to ce tin co-fac tor (VWF:R Co) as say, 
whi ch as ses ses the abi li ty of VWF to bi nd to pla te-
le ts in the pre sen ce of ris to ce tin, and the col la gen 
bin di ng (VWF:CB) as say, whi ch as ses ses the abi li ty 
of VWF to bi nd to su b-en dot he lial mat rix pro tei ns 
(in this ca se col la gen) (33). De pen di ng on the VWF 
as say, a va rie ty of tec hniques may be used; in clu di-
ng en zyme-lin ked im mu noab sor be nt as says (ELI-
SAs), la tex im mu noas says (LIAs), and pla te let ag-
glu ti na tion as says. Se ve ral as say li mi ta tio ns are 
evi de nt wi th the se tes ts, in clu di ng as say rep ro du-
ci bi li ty (34) and lower li mit of sen si ti vi ty (35) is sues. 
The VWF:CB ten ds to be mo re sen si ti ve to HMW 
VWF, al so su_ e rs le ss va ria bi li ty than the VWF:R Co, 
and has bet ter lower li mit of sen si ti vi ty pro per ties. 
No net he le ss, as the VWF:CB reZ ec ts a di_ e re nt 
fun ctio nal pro per ty of VWF than the VWF:R Co, bo-
th tes ts are requi red to iden ti fy all pos sib le for ms 
of VWD (32,33). Se ve ral ot her hig hly spe cia li zed 
pro ce du res are avai lable to he lp fun ctio nal ly 
charac te ri ze or clas si fy VWD (32,36–38), in clu di ng 
the ris to ce tin indu ced pla te let aggre ga tion (RIPA) 
pro ce du re (typi cal ly per for med as a pa rt of pla te-
let fun ction tes ti ng), VWF:mul ti mer ana lysis (to he-
lp as se ss for struc tu ral de fects ari si ng from al te red 
VWF as sem bly or pro teo lysis) and VWF:FVIII bin-
di ng (VWF:FVIIIB).
Pla te let fun ction tes ti ng
This can be ac hie ved usi ng com pre hen si ve pla te-
let ag gre ga tion tes ti ng (11–14) or usi ng a scree-
ni ng test pro ce ss (e.g., PFA-100) (39,40). The lat ter 
can be used to pro vi sio nal ly iden ti fy a pla te let de-
fe ct, or an ti-pla te let me di ca tion a_ e ct (e.g., as pi-
rin), but com pre hen si ve pla te let tes ti ng is requi red 
to iden ti fy and cha rac te ri ze spe ci fic qua li ta ti ve 
pla te let di sor de rs. This lat ter pro ce ss is com plex 
and tec hni cal ly de man di ng, and in vol ves chal len-
gi ng pa tie nt ma te rial eit her as pla te let ri ch plas ma 
(usi ng lig ht tran smis sion ag gre go met ry) or as 
who le blood (usi ng a who le blood ag gre go me ter) 
wi th various pla te let ago nis ts (11–14,41).
Throm bophi lia tes ti ng
Labo ra to ry tes ti ng may in clu de as says to de te ct 
con ge ni tal de X  cien cies or de fec ts in the na tu ral 
an ti coa gu lan ts (i.e., PC, PS, AT), or acqui red de fec ts 
re la ted to the pre sen ce of aPL. Con ge ni tal de X -
cien cies in PC, PS and AT are ra re, and most de fec-
ts iden ti X ed by la bo ra to ry tes ti ng are acqui red, 
due to li ver di sea se, vi ta min K de X  cien cy, DIC, or 
an ti-coa gu la nt me di ca tion (15). Bo th fun ctio nal 
and an ti ge nic as says are avai lab le for the se te st 
pa ra me te rs, wi th fun ctio nal as says bei ng do-
minant for PC and AT (usual ly chro mo ge nic as-
says), and an ti ge nic as says bei ng do mi na nt for PS 
(usual ly LIA or ELISA). Ac ti va ted pro tein C (APC) re-
sis tan ce (APCR) is de X  ned as an im pai red plas ma 
an ti coa gu la nt res pon se to APC ad ded in vit ro, and 
a re la ti ve inabili ty to inac ti va te FVa and/or FVIIIa. 
The main mo le cu lar ba sis of APCR was iden ti X ed 
in 1994 and com pri ses a poi nt mu ta tion in the ge-
ne for FV, now ter med FV Lei den (FVL). The re are 
two main la bo ra to ry met ho ds used for tes ti ng 
APCR, the ori gi nal AP TT-based met hod and Rus se-
ll viper venom time (RVVT) ba sed met ho ds (42). 
One of the mo st com mon and cli ni cal ly im por ta nt 
cau ses of acqui red throm bop hi lia, APS, is as ses sed 
by a pa nel of tes ts that mea su re aPL (au toan ti bo-
dies that re cog ni ze epi to pes on se lec ted protei ns 
when bou nd to phos pho li pid sur fa ces). The se in-
clu de lu pus an ti coa gu la nt (LA), whi ch can be as-
ses sed usi ng a va rie ty of te st pro ces ses, al thou gh 
the up da ted LA gui de li nes from the Scien ti fic 
Stan dar di za tion Sub com mit tee (SSC) of the In ter-
na tio nal Society on Throm bo sis and Hae mos ta sis 
(ISTH) re com me nd the com bi ned use of APTT and 
RVVT ba sed as says, to get her wi th so lid pha se as-
says (43).
Fac tor inhi bi to rs
Spe ci X c in hi bi to rs can de ve lop again st any in di vi-
dual coa gu la tion fac tor and cau se a de X  cien cy 
that can be de tec ted by pro lon ged PT and/or 
APTT (44). Mo re cli ni cal ly im por ta nt is that the se 
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pa tien ts can su_ er se rious blee di ng prob le ms (45). 
Whi le so me pa tien ts can de ve lop in hi bi to rs af ter 
treat me nt wi th plas ma pro duc ts (e.g., hae mop hi lia 
pa tien ts that de ve lop al loan ti bo dies), ot he rs can 
de ve lop in hi bi to rs se con da ry to so me ot her di sea-
se pro ce ss (e.g., au toan ti bo dies that lead to an 
acqui red hae mop hi lia), and ot he rs can be idio pat-
hic (un known cau se). Af ter an in hi bi tor is iden ti X ed 
throu gh mixi ng studies in a rou ti ne coa gu la tion 
te st system (i.e., PT and/or APTT, de pen di ng on 
whi ch in hi bi tor is pre se nt or whi ch te st was pro-
lon ged), a spe ci X c in hi bi tor as say can be per for-
med usi ng a Bet hes da as say or Nij me gen mo di X -
ca tion (44,46). The mo st com mon type of in hi bi tor 
is that again st FVIII.
Qua li ty con trol and extra-a na lyti cal 
is sues in hae mos ta sis tes ti ng
Un for tu na te ly, the la bo ra to ry tes ti ng pro ce ss is 
not prob lem free. The re are ma ny ste ps in the pro-
ce ss of la bo ra to ry tes ti ng whe re the pro ce ss can 
go awry and the re fo re mu st be con trol led. In or-
der to en su re the ap prop ria te ne ss of te st re sul ts, 
la bo ra to ries are requi red to put se ve ral qua li ty 
pro ces ses in to pla ce, and na me ly to un der ta ke 
per for man ce of bo th in ter nal qua li ty con trol (IQC) 
and exter nal quali ty as su ran ce (EQA). Qua li ty con-
trol pro vi des a pro ce ss to mo ni tor a num ber of va-
riab les that may in clu de pre-a na lyti cal, ana lyti cal, 
po st-a na lyti cal and in ter pre ta ti ve er ror. For exam-
ple, the re are a va st num ber of pre-a na lyti cal va-
riab les in hae mos tasis. The se are of ten beyo nd the 
con trol of the te st la bo ra to ry, and are not always 
ea si ly iden ti X ab le. As de tai led be low, they com pri-
se is sues that oc cur prior to tes ti ng and in clu de 
spe ci X  cs re la ted to col lec tion (e.g., wro ng tu be 
type, wro ng col lec tion order, sam ple mis la be li ng, 
e tc), and tran spo rt (e.g., sam ples le ft at extre mes 
of tem pe ra tu re) and inap prop ria te pro ces si ng of 
the sam ple. Pre-a na lyti cal is sues can lead to se-
rious ad ver se a_ ec ts on the te st and thus sub-
seque nt pa tie nt ca re (7). Ana lytical va riab les that 
may cau se prob le ms in tes ti ng in clu de inap prop-
ria te rea ge nt/instrument ca lib ra tio ns, rea ge nt is-
sues (e.g., not pro per ly re con sti tu ted or used bey-
o nd sta bi li ty), met ho do lo gi cal is sues (poor met ho-
do lo gies), and in stru me nt prob le ms (e.g., detec tor 
syste ms fai li ng or ina dequa te sam pli ng). Po st-a na-
lyti cal and in ter pre ta ti ve is sues (7,47) re la te to the 
in ter pre ta tion of the te st re su lt by the la bo ra to ry 
(in clu di ng the is sued re po rt) and/or the cli ni cian 
(who in ter pre ts the re por ted te st re sul ts). In cor po ra-
tion of qua li ty mea su res is ai med at iden ti fyi ng and 
cor rec ti ng prob le ms re la ted to all the se as pec ts of 
tes ti ng (i.e., pre-a na lyti cal, ana lyti cal and po st-a na-
lyti cal) to en su re hi gh qua li ty tes ti ng re sul ts.
Prea na lyti cal va riab les
La bo ra to ry data mu st be ac cu ra te and re liab le as 
er ro neous re sul ts may lead to pa tie nt mis diag no-
sis and the re fo re the ra peu tic mi sad ven tu res. Inac-
cu ra cy in la bo ra to ry re por ti ng can ari se due to 
prob le ms in tro du ced at any poi nt in the tes ti ng 
pro ce ss, from sam ple col lection to re po rt re sul ts. 
Due to sig ni X  ca nt ad van ces in in stru men ts and in-
for ma ti cs, the ana lyti cal and re por ti ng pha ses of 
tes ti ng do not con tri bu te sig ni X  can tly to la bo ra to-
ry er ror. Rat her, the pre-a na lyti cal pha se of tes ti ng 
rep re sen ts the ma jor sour ce of inac cu ra te la bo ra-
to ry re sul ts (48,49).
The pre-a na lyti cal pha ses of tes ti ng in clu de spe ci-
men col lec tion, tran spor ta tion of who le blood 
spe ci me ns to the la bo ra to ry, spe ci men pro ces si ng 
and sto ra ge (50). One of the mo st cri ti cal as pec ts 
of spe ci men col le ction is pro per pa tie nt and al so 
sam ple iden ti X  ca tion. Spe ci me ns mu st be col lec-
ted in a man ner to avoid in vit ro clot de ve lop me nt. 
Sam ples shou ld be col lec ted in a re la ti ve ly at rau-
ma tic fas hion and blood shou ld Z ow free ly in to 
the spe ci men con tai ner.
Samples for hae mos ta sis tes ti ng shou ld be an ti-
coa gu la ted wi th so dium cit ra te. The Wor ld Heal th 
Or ga ni za tion (WHO) and CLSI re com me nd 3.2% 
so dium cit ra te, al thou gh 3.8% mig ht al so be ac-
cep tab le. It is im por ta nt that the con cen tra tion of 
so dium cit ra te is con siste nt wit hin a la bo ra to ry 
system as clot ti ng ti mes te nd to be lon ger in 3.8% 
ver sus 3.2% so dium cit ra te. The blood and an ti-
coa gu la nt mu st be prom ptly mixed to avoid in vit-
ro clot for ma tion. Sam ples for hae mos ta sis tes ti ng 
that con tain vi sib le clo ts shou ld not be ana lyzed 
and mu st be re jec ted. The requi red blood to an ti-
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coa gu la nt ra tio is 9:1 and the re fo re over X l li ng or 
un der X l li ng of the eva cua ted tu be shou ld be avoi-
ded as this can in tro du ce re su lt er ror. Ot her an ti-
coa gu lan ts su ch as et hyle ne dia mi ne tet raacetic 
acid (EDTA) or he pa rin are not ac cep tab le for hae-
mos ta sis tes ti ng. Sam ples col lec ted in EDTA or he-
pa rin an ti coa gu la ted tu bes or the use of se rum for 
hae mos ta sis tes ti ng wi ll lead to aber ra nt re sul ts 
and this can cau se cli ni cal ly sig ni X  ca nt er ro rs in 
patie nt diag no sis. So me la bo ra to ries re cei ve a por-
tion or ma jo ri ty of te st sam ples in se con da ry (ali-
quot) tu bes and in this in stan ce, the sam ple types 
are in dis tin guis hab le un le ss clear ly and pro per ly 
la be led as so dium cit ra te plas ma, EDTA plas ma, 
he pa rin plas ma or se rum. When the sam ple mat rix 
is un known or in dou bt, per for man ce of so dium, 
po tas sium and cal cium as says on the sam ple can 
be un der ta ken to he lp de ter mi ne the sam ple mat-
rix. Sam ples col lec ted in so dium cit ra te te nd to ha-
ve hi gh so dium and low calcium va lues whi le sam-
ples col lec ted in po tas sium EDTA wi ll ha ve ele va-
ted po tas sium le ve ls wi th un de tec tab le cal cium 
va lues (51). Sam ples for hae mos ta sis tes ti ng col lec-
ted in the wro ng an ti coa gu la nt tu be or se rum 
sam ples shou ld not be ana lyzed and mu st be re-
jec ted.
Sta bi li ty of hae mos ta sis sam ples de pen ds on whi-
ch as say(s) are to be per for med as we ll as the tem-
pe ra tu re and con di tio ns of sto ra ge. Fol lowi ng col-
lec tion, sam ples shou ld be tran spor ted to the la-
bo ra to ry at room tem pe ra tu re prom ptly, ideal ly 
within one hour of drawi ng. Co ld sto ra ge of cit ra-
ted who le blood, eit her by pla ci ng sam ples in an 
ice ba th or ref ri ge ra ted (2–8 ºC) may lead to ac ti-
va tion of pla te le ts, ac ti va tion of fac tor VII and sig-
ni X  ca nt ti me de pen de nt lo ss of bo th FVIII and 
VWF. De pe nding on the tes ts or de red and whet-
her un frac tio na ted he pa rin is pre se nt in the spe ci-
men, sam ples can be sto red eit her as who le blood 
or cen tri fu ged and the plas ma le ft re mai ni ng on 
the red cel ls or the plas ma aliquo ted.
In sum ma ry:
• Sam ples for pla te let function tes ti ng shou ld re-
main at room tem pe ra tu re and tes ti ng com ple-
ted wit hin 3 to 4 hou rs of col lec tion.
• Sam ples for PT/INR eva lua tion are stab le at 
room tem pe ra tu re for 24 hou rs. Sam ples can 
be sto red as who le blood or cen tri fu ged.
• Sam ples con tai ni ng un frac tio na ted he pa rin 
mu st be pro ces sed wit hin 1 hour of col lec tion 
be cau se of re lea se of PF4 from pla te le ts in vit ro 
whi ch neut ra li zes the he pa rin lea di ng to spu-
rious ly low he pa rin le ve ls as mea su red by an 
APTT or an ti-FXa as say. If the who le blood is 
cen trifuged wit hin 1 hour, the he pa ri ni zed plas-
ma can be le ft at room tem pe ra tu re for up to 
four hou rs prior to tes ti ng.
• Sam ples for APTT tes ti ng that do not con tain 
un frac tio na ted he pa rin and sam ples for spe cial 
coa gu la tion as says shou ld be main tai ned at 
room tempe ra tu re if tes ti ng wi ll be com ple te 
wit hin four hou rs. Sam ples that can not be tes-
ted in this ti me fra me shou ld be spun and the 
plas ma fro zen in a free zer that does not un der-
go au to ma tic free ze thaw cycles.
Sam ples shou ld be cen tri fu ged to ob tain pla telet 
poor plas ma con tai ni ng ≤ 10 x 109 pla te le ts/L. In 
or der to en su re ap prop ria te re mo val of pla te le ts 
for so me par ti cu lar ly sen si ti ve tes ts in clu di ng LA, a 
pro ce ss of doub le cen tri fu ga tion is re com men ded 
(7,43). This is es pe cial ly im por ta nt if the plas ma will 
be fro zen prior to tes ti ng. The use of mic ro po re X l-
te rs to re mo ve pla te le ts is not re com men ded sin ce 
this X l tra tion pro ce ss can lead to lo ss of fac tors V, 
VIII, IX, XII and VWF (43,54). Sam ples that are sto-
red fro zen shou ld re main at –20 ºC for no more 
than two wee ks. Prior to tes ti ng, sam ples shou ld 
be com ple te ly thawed in a 37 ºC wa ter ba th (for 
about 5 mi nu tes) and mixed tho roug hly prior to 
tes ti ng. Re pea ted free ze/thaws shou ld be mi ni mi-
zed, to re tain sam ple in teg ri ty.
In ter nal qua li ty con trol (IQC)
IQC mu st be ana lyzed wi th ea ch as say per for med 
wit hin the la bo ra to ry. The pur po se of IQC is to as-
se ss on goi ng as say per for man ce to en su re that as-
says are per for mi ng ac cor di ng to spe ci X  ca tio ns to 
en su re re sul ts that are ac cu ra te and re liab le. IQC 
ma terial ge ne ral ly in clu des ‘nor mal’ and ‘ab nor-
mal’ sam ple con tro ls wi th re sul ts plot ted usi ng a 
Le vy-Jen nin gs cha rt. This pro ce ss is per for med for 
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ea ch ana lyte tes ted (i.e., PT, APTT, e tc), and usi ng a 
ti me-fra me sui ted to ea ch te st per for med. For 
exam ple, for con ti nuous te st syste ms su ch as 
APTT, it mig ht be ap prop ria te to per fo rm tes ti ng 
eve ry two, four or so hou rs. For tes ts per for med in 
bat ches, it mig ht be ap prop ria te to per fo rm con-
tro ls at the sta rt, mid dle and end of the te st run. 
When IQC fal ls out of the expec ted ran ge, la bo ra-
to ries can re fer to se ve ral ru les (e.g., Wes tga rd Ru-
les; avai lab le at: www.westgard.com) to de ter mi ne 
if the as say is sti ll per for mi ng adequa te ly or if in-
stru me nt/assay troub les hoo ti ng is requi red. For 
exam ple, when IQC re sul ts are Z ag ged as bei ng 
out of the expec ted ran ge by mo re than three 
stan da rd de via tio ns, the la bo ra to ry shou ld be aler-
ted and the prob lem in ves ti ga ted and re sol ved. 
Re sul ts from that par ti cu lar run shou ld not be re-
por ted un til the out of ran ge IQC is sue is ad-
dressed. Re cor ds shou ld be ke pt of chan ges in lot 
num be rs of rea gen ts and va ria tion be tween rea-
ge nt lo ts mo ni to red. Re ca lib ra tion may be requi-
red for spe ci X c as says (e.g., new stan da rd cur ve for 
spe ci X c fac tor as says). IQC can be rea di ly and ea si-
ly ap plied to mo st diag nos tic hae mos ta sis as says. 
Se ve ral le ve ls of con tro ls are uti li zed for ea ch and 
eve ry te st ana lyte. So me exam ples are gi ven in 
Tab le 1.
In con tra st, a re view of the IQC (a nd EQA) for pla-
te let ag gre ga tion tes ti ng em pha si zes the strug-
gle diag nostic la bo ra to ries may fa ce pro vi di ng 
adequa te qua li ty con trol for par ti cu lar tes ts. In this 
in stan ce, for exam ple, one is sue com pri ses the col-
lec tion and tran spo rt of fre sh blood to pro vi de 
fun ctio nal pla te le ts for tes ti ng. An im por ta nt fun-
ction of IQC is to en su re rep ro du ci bi li ty of tes ti ng. 
Te st (ab bre via tion) Le vel 1 con trol tar get Le vel 2 con trol tar get Op tio nal/ ad di tio nal con tro ls and 
com men ts
Rou ti ne coa gu la tion 
tes ts (i.e., PT, INR, 
APTT, TT).
Mid poi nt of nor mal 
re fe ren ce ran ge
Mid poi nt of the ra peu tic 
(an ti coa gu la nt the ra py) ran ge 
(hi gh le vel)
Hi gh end of the ra peu tic or ab nor mal 
ran ge
Fib ri no gen Low end or mid poi nt of 
nor mal re fe ren ce ran ge
Mid poi nt of ab nor mal (low le vel) 
range
Hi gh end con trol if throm bo si s-ri sk is 
bei ng as ses sed.
D-di mer Low end or mid poi nt of 
nor mal (ne ga ti ve) re fe ren ce 
ran ge (ne ga ti ve con trol)
Mid poi nt of ab nor mal (po si ti ve) 
ran ge (po si ti ve con trol)
Hi gh end for quan ti ta ti ve as says, 
es pe cial ly if DIC is being ‘mo ni to red’
Fac tor as says 
(FII, FV, FVII, FVIII, 
FIX, FX, FXI, FXII)
Low end or mid poi nt of 
nor mal re fe ren ce ran ge 
(i.e., 90–100%)
Mid poi nt of ab nor mal (low le vel) 
ran ge (i.e., 20–40%)
Fac tor de X  cie nt plas ma to iden ti fy 
lower as say li mit; hi gh-e nd control 
(≥150%) for quan ti ta ti ve as says if 
throm bo si s-ri sk is bei ng as ses sed.
FXIII Nor mal plas ma (ne ga ti ve 
con trol) 
FXIII de X  cie nt plas ma (po si ti ve 
con trol)
VWF as says Low end or mid poi nt of 
nor mal re fe ren ce ran ge 
(i.e., 90–100%)
Mid poi nt of ab nor mal (low le vel) 
ran ge (i.e., 20–40%)
VWF de X  cie nt plas ma to iden ti fy lower 
as say li mit; hi gh-e nd con trol (≥150%) for 
quan ti ta ti ve as says if throm bo si s-ri sk 
is bei ng as ses sed; qua li ta ti ve (Type 2 
VWD-li ke) con trol.
PC, PS, AT Low end or mid poi nt of 
nor mal re feren ce ran ge
Mid poi nt of ab nor mal (low le vel) 
ran ge, or he te ro zygous pat te rn 
con trol
APCR Low end or mid poi nt of 
nor mal re fe ren ce ran ge
Mid poi nt of ab nor mal (low le vel) 
ran ge, or he te ro zygous pat te rn 
con trol
LA Ne ga ti ve con trol Po si ti ve con trol (weak posi ti ve 
near as say cu t-o _ )
Posi ti ve con trol (mo de ra te or stro ng 
po si ti ve)
TAB LE 1. Sam ple qua li ty con trol spe ci X  ca tio ns for coa gu la tion and hae mos ta sis.
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For pla te let ag gre ga tion this shou ld the re fo re 
ideal ly in clu de a nor mal (a nd ideal ly an ab nor mal) 
con trol wi th eve ry bat ch of pla te let fun ctio ns per-
for med. A nor mal (a nd an ab nor mal) con trol shou-
ld al so be run wi th each new lot of rea gen ts. Al-
thou gh this may seem sim ple it is not wit hout its 
chal len ges. Com mer cial con trol ma te rial does not 
exi st. Ab nor mal con trol ma te rial wou ld need to be 
ob tai ned from pa tien ts wi th known de fec ts, or on 
an ti-pla te let agen ts. The pro vi sion of nor mal do-
no rs to pro vi de fre sh pla te le ts is al so an is sue, par-
ti cu lar ly for sma ll la bo ra to ries whe re ‘vo lun tee rs’ 
may be in sho rt sup ply. The re are al so ob vious et-
hi cal is sues re la ted to the se in va si ve pro ce du res 
bei ng re gu lar ly re pea ted on nor mal and pa tie nt 
‘vo lun tee rs’. The cur re nt CLSI gui de li nes (52) sta te; 
“It is good la bo ra to ry prac ti ce that [pla te let fun ctio n] 
rea gen ts are tes ted wi th a nor mal pla te let con trol ea-
ch ti me an ag gre ga tion stu dy is per for med; one may 
plot the se cu mu la ti ve va lues on a QC cha rt to as se ss 
their po ten cy”. Howe ver, whi le this can be ac hie ved 
in lar ge la bo ra to ries (55), it is not typi cal ly fea sib le 
for mo st te st la bo ra to ries. Ot her in ter na tio nal gui-
de li nes on pla te let fun ction tes ti ng ai mi ng to pro-
vi de diag nos tic la bo ra tories wi th gui dan ce on 
sam ple col lec tion, pro ces si ng and ana lysis are cur-
ren tly bei ng for mu la ted by mem be rs of the ISTH.
Exter nal qua li ty as su ran ce
EQA des cri bes a di_ e re nt and sup ple men ta ry pro-
ce ss to IQC. EQA is a peer group as ses sme nt pro ce-
ss that al lows a la bo ra to ry to as se ss in di vi dual ana-
lytes again st tho se of ot her la bo ra to ries usi ng eit-
her the sa me or di_ e re nt rea gen ts or in stru men ta-
tion. EQA al so pro vi des a mea ns to eva lua te lo ng-
te rm per for man ce of la bo ra to ries. For hae mos ta sis 
tes ti ng, the analytes as ses sed by EQA prog ra ms 
are tho se used in the diag no sis and treat me nt of 
blee di ng and throm bo tic di sor de rs. As we ll as pro-
vi di ng an exter nal as ses sme nt of la bo ra to ry te st 
per for man ce, mo st EQA pro vi de rs al so o_ er edu-
ca tio nal sup po rt for la bo ra to ries, eit her throu gh 
expe rt ad vi ce or via the dis tri bu tion of writ ten 
pub li ca tio ns. In ad di tion, mo st EQA pro vi de rs dis-
tri bu te and col la te ques tion nai res re la ted to cur re-
nt prac ti ce, whi ch al so in fo rm par ti ci pan ts on va-
rious to pi cs of in te re st, and pro vi de additio nal in-
for ma tion on rea gen ts, in stru men ta tion and la bo-
ra to ry prac ti ces.
As ses sme nt cri te ria uti li zed by EQA pro vi de rs may 
va ry from prog ram to prog ram. EQA re por ts typi-
cal ly per mit la bo ra to ries to al so un der ta ke se lf-as-
ses sme nt of their own re sul ts co mpared to tho se 
of their pee rs. In di vi dual la bo ra to ry bias and dri ft 
can be mo ni to red as we ll as ac cu ra cy and pre ci-
sion. For exam ple, the Royal Col le ge of Pat ho lo gis-
ts of Aus tra la sia (RCPA) Hae ma to lo gy Qua li ty As su-
ran ce Prog ram (QAP) pro vi des par ti ci pan ts with 
sum ma ry da ta for an en ti re year’s prog ram to gi ve 
an over view of lo ng-te rm la bo ra to ry per for man ce. 
End of cycle (EOC) re por ts al so pro vi de a sta tis ti cal 
ana lysis of the re sul ts for ea ch ana lyte over the 
sur vey year.
Par ti ci pa tion in a prog ram that o_ ers EQA is of ten 
a requi re me nt for la bo ra to ry ac cre di ta tion by re-
gu la to ry aut ho ri ties (56). For exam ple, wit hin Aus-
tra lia, me di cal la bo ra to ry ac cre di ta tion is con duc-
ted by a bo dy cal led NATA (Na tio nal As so cia tion of 
Tes ti ng Aut ho ri ties), whi ch as ses ses all Austra lian 
diag nos tic hae mos ta sis la bo ra to ries on a three-
year ba sis. In the U.S. this is lar ge ly ac com plis hed 
by the Col le ge of Ame ri can Pat ho lo gis ts (CAP). Du-
ri ng the se as ses smen ts, the re sul ts from the EQA 
prog ram are exa mi ned and any ana lytes out si de 
of de X  ned ‘al lowab le li mi ts of per for man ce’ need 
to be iden ti X ed as bei ng ac tio ned or in ves ti ga ted 
by the la bo ra to ry, and an expla na tion of any dis-
cre pan cies nee ds to be re cor ded. If the prob lem 
oc cu rs over mo re than one sur vey then the la bo ra-
to ry nee ds to be proac ti ve in sol vi ng the is sue. 
Mo reo ver, the EQA pro vi de rs are them sel ves al so 
mo ni to red by the se go ver nme nt re gu la to ry bo-
dies. For exam ple, the RCPA Hae ma to lo gy QAP is 
ac cre di ted by NATA and al so as ses sed on a three-
year ba sis.
Im por tan ce of exter nal qua li ty as su ran ce
The re are ma ny in ter na tio nal ly re cog ni zed EQA 
prog ra ms, al thou gh se ve ral are pro mi ne nt in the 
area of coa gu la tion and hae mos ta sis (57–60). The-
se in clu de the RCPA Hae ma to lo gy QAP, the UK-ba-
sed NEQAS (Na tio nal Exter nal Qua li ty As su ran ce 
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Sche me), the Eu ro pean ba sed ECAT, and the US 
ba sed CAP (Col le ge of Ame ri can Pat ho lo gis ts) and 
NASCOLA (Nor th Ame ri can Spe cia li zed Coa gu la-
tion La bo ra to ry As so cia tion). The re are al so se ve ral 
Na tio nal prog ra ms that con du ct EQA prog ra ms 
wit hin mo re lo ca li zed regio ns su ch as in di vi dual 
coun tries. All prog ra ms ha ve va lue, al thou gh eco-
no mies of sca le for so me ana lytes wou ld fa vor the 
lar ger or in ter na tio nal prog ra ms. Thus, EQA for 
rou ti ne coa gu la tion tes ti ng wou ld lar ge ly be co ve-
red by all EQA prog ra ms that o_ er coa gu la tio n-ba-
sed prog ra ms, al thou gh lo cal or Na tio nal prog ra-
ms wou ld li ke ly do mi na te, whe reas as ses sme nt of 
ana lytes for the mo re spe cia li zed tes ts of hae mos-
ta sis (e.g., VWF, fac tor in hi bi to rs, e tc) wou ld on ly 
be pro vi ded by so me of the in ter na tio nal EQA 
prog ra ms.
In any ca se, it is throu gh the se EQA prog ra ms that 
la bo ra to ries can mo ni tor, im pro ve and es tab li sh 
good la bo ra to ry prac ti ce in or der to en su re ac cu-
ra cy, pre ci sion and qua li ty of tes ti ng. This in tu rn 
wi ll pro vi de mo re cor re ct diag no ses and sa fer pa-
tie nt ca re by cli ni cia ns, whi ch is the main pur po se 
of la bo ra to ry pro ce du res. The fol lowi ng pa rag rap-
hs hig hlig ht so me re ce nt ini tia ti ves by va rious EQA 
pro vi de rs.
Rou ti ne coa gu la tion tes ti ng
Mo st pub li ca tio ns about the eva lua tion of rou ti ne 
coa gu la tion tes ti ng re la te to their ap pli ca tion wit-
hin the in ves ti ga tion of spe ci X c di sor de rs (see fol-
lowi ng sec tio ns) or to INR mo ni to ri ng of an ti coa-
gu la nt the ra py or to D-di mer tes ti ng. Wi th res pe ct 
to the bo th INR and D-di mer, ma ny on goi ng is sues 
ha ve been hig hlighted by EQA pro vi de rs. For ex-
am ple, er ro rs in the equa tion used to cal cu la te INR 
or er ro rs in the con ver sion of uni ts used in re por ti-
ng quan ti ta ti ve D-di mer as says (57–62).
Throm bop hi lia tes ti ng
Sin ce bo th te st met ho do lo gy and the com po si te 
tes ts per for med wit hin a pa nel can a_ e ct the ac-
cu ra cy of the de tec tion of spe ci X c throm bop hi lia 
mar ke rs, as ses sme nt of tes ti ng prac ti ce by eva lua-
tion of la bo ra to ry ba sed te st pro fi cien cy usi ng 
mul ti-la bo ra to ry sur veys (EQA) is con si de red a ba-
sic ne ces si ty in la bo ra tory prac ti ce.
Lu pus an ti coa gu la nt (LA)
Becau se of the he te ro ge nei ty of LA an ti bo dies and 
the de pen den ce of the la bo ra to ry tes ti ng on the 
cli ni cal diag no sis, re lia bi li ty in the ma ny di_ e re nt 
as says used to de te ct aPL is nee ded. Te st per for-
man ce gui de li nes have re cen tly been up da ted by 
the ISTH SSC (43). Des pi te the se e_ or ts, tes ti ng re-
mai ns pla gued by a plet ho ra of met ho do lo gi cal is-
sues and no n-stan dar di za tion in te st prac ti ce (18). 
The CAP pub lis hed an eva lua tion on the e_ e ct of 
LA on rou ti ne coa gu la tion fac tor as says in 1986 
and 1987 (63). At that ti me, the APTT rea gen ts va-
ried in their sen si ti vi ty to LA lea di ng to the con clu-
sion that la bo ra to ries nee ded to be ca re ful in their 
se lec tion of APTT rea gen ts for de tec ti ng LA. Al so 
no ted was the po ten tial for a stro ng LA to in ter fe-
re wi th the FVIII as say cau si ng fal se ly low le ve ls for 
all APTT rea gen ts wi th a hi gh tit re LA.
Over a pe riod of three yea rs, NEQAS eva lua ted re-
sul ts re tur ned by par ti ci pan ts for a weak, stro ng 
and ab se nt LA sam ples (64). The tes ti ng was per-
for med in 220 cen te rs and the APTT, dR VVT (di lu te 
RVVT) and KCT (kao lin clot ti ng time) re sul ts we re 
eva lua ted. The abi li ty of in di vi dual la bo ra to ries to 
ma ke an ap prop ria te diag no sis was in Z uen ced by 
se lec tion and ap pli ca tion of the te st tec hnique. 
The pre sen ce of a stro ng LA was not de tec ted by 
4% of la bo ra to ries, wi th the cor re ct diag no sis bei-
ng ma de by 94% of dR VVT use rs and 85% of KCT 
use rs. A weak LA was not de tec ted by over ha lf of 
the tes ti ng cen te rs. Im pro ve men ts in tes ti ng for 
LA we re fou nd by this EQA pro vi der in a la ter sur-
vey af ter dis se mi na tion of na tio nal gui de li nes on 
la bo ra to ry met ho ds (65).
The RCPA Hae ma to lo gy QAP has over the la st 10 
yea rs eva lua ted over 20 LA sur vey sam ples dis tri-
bu ted to par ti ci pan ts (mo st we re va rious gra des of 
posi ti ve for LA, a few we re nor mal or equi vo cal). 
Mo st la bo ra to ries used a pa nel of tes ts in clu di ng 
the APTT (100% of par ti ci pan ts), KCT (26–76%), and 
dR VVT (75–100%). Coet   cien ts of va ria tio ns (CVs) 
for as says ha ve ran ged from 5 to 40%. dR VVT ap-
pea red to be the mo st sen si ti ve and spe ci X c for 
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de tec tion of LA, al thou gh la bo ra to ries per for med 
be st when they used a pa nel of tes ts (66). The ove-
ra ll er ror rate was ge ne ral ly < 5%, and was in pa rt 
de pen de nt on the stren gth of the LA (hig her ra tes 
for wea ker LA). Al thou gh the the n-cur re nt LA gui-
de li nes we re fol lowed by the ma jo ri ty of par ti ci pa-
nt la bo ra to ries, in ter pre ta ti ve er ro rs we re of ten 
pro du ced by the sma ll num ber of la bo ra to ries that 
did not.
NASCOLA and ECAT ha ve al so as ses sed and re por-
ted on per for ma nce of LA tes ti ng, wi th NASCOLA 
re cen tly iden ti fyi ng a hi gh fal se ne ga ti ve ra te of 
35–40%, and iden ti fyi ng that so me 25% of la bo ra-
to ries did not com ply wi th ISTH re com men da-
tions (67).
AT, PC, PS and APCR
A diag nos tic er ror ra te of 2–10% has been ob ser-
ved for AT, PC, PS, and APCR from par ti ci pan ts of 
the RCPA QAP, wi th bo th te st type and te st met ho-
do lo gy con tri bu ti ng to this (66). The be st per for-
mer is the AT as say, whi le the wor st are the PS as-
says (bo th to tal and free PS as says) wi th CVs reac-
hi ng 30%. Tests for PC al so su_ er from so me deg-
ree of va ria bi li ty, and bo th PC and PS clo t-ba sed 
as says may on oc ca sion be in Z uen ced by the pre-
sen ce of APCR. Si mi lar X n din gs ha ve al so been re-
por ted by the NEQAS and ECAT (68,69). The APCR 
as say er ror ra tes we re greater for the AP TT-ba sed 
met hod (even when FV de X  cie nt plas ma was ad-
ded to the te st system) than the RVVT-ba sed met-
hod, whi ch per for med we ll even wit hout the ad di-
tion of FV de X  cie nt plas ma (66).
Fac tor in hi bi tor in ves ti ga tio ns
This has re cen tly been re ported by va rious EQA 
pro vi de rs (70–76). In brief, hi gh in te r-as say va ria bi-
li ty in as say re sul ts has been con sis ten tly ob ser ved 
in all re por ts, wi th lit tle or no im pro ve me nt over 
the pa st de ca de. Al so con cer ni ng is the la ck of 
stan dar di za tion ac ro ss la bo ra tories, wi th no two 
la bo ra to ries iden ti X ed as per for mi ng the sa me te-
st pro ce du re in a re ce nt eva lua tion from the RCPA 
Hae ma to lo gy QAP (72,73). Ove ra ll, the Nij me gen 
met hod ap pea rs to per fo rm slig htly bet ter than a 
stan da rd Bet hes da met hod.
Von Wil leb ra nd factor/ von Wil leb ra nd 
di sea se in ves ti ga tio ns
In the pe riod of 2003–2005, CAP eva lua ted the 
per for man ce of 160 to 219 la bo ra to ries usi ng three 
di_ e re nt lyop hi li zed plas mas wi th VWF an ti gen le-
ve ls of 25%, 50% and 100% (77). The re sul ts 
showed hi gh ac cu ra cy for the VWF:Ag and VWF:R-
Co ac ti vi ty as say, wi th a ll-met hod mean va lues fal-
li ng be tween 3.2% and 5.6% res pec ti ve ly. Howe-
ver, whil st the VWF:Ag as say showed mo de ra te 
pre ci sion, wi th all CVs ran gi ng from 10.7% to 15.1%, 
the VWF:R Co as say showed low pre ci sion, wi th all 
met hod CVs ran gi ng from 23.3 to 30.9%. Pre ci sion 
in crea sed as the VWF con cen tra tion in crea sed for 
all as says.
The RCPA Hae ma to lo gy QAP has dis pat ched a to-
tal of near ly 60 plas ma sam ples to par ti ci pan ts for 
VWD eva lua tion over the yea rs 1998 to 2009 
(34,35,78). The se sam ples ha ve in clu ded plas ma 
from nor mal in di vi dua ls plus all of the ma jor VWD 
sub types (Type 1, Type 2A, 2B, 2M, 2N, and Type 3). 
FVIII:C was per for med by all par ti ci pa ti ng la bo ra-
to ries. VWF:Ag was per for med by all par ti ci pan ts 
in ea rlier sur veys, but in mo re re ce nt sur vey a few 
la bo ra to ries ha ve not in clu ded this in their pa nel 
of tes ts. The VWF:R Co as say was per for med by > 
90% of par ti ci pan ts in ear lier sur veys, but this has 
drop ped to ~ 60% of par ti ci pan ts in mo re re ce nt 
sur veys, indica ti ng that ma ny la bo ra to ries ha ve 
cea sed usi ng this as say. Usa ge of the VWF:CB as say 
has been fair ly con sis te nt over the yea rs wi th ~ 
50% of par ti ci pan ts per for mi ng the as say. Grea ter 
than 80% of par ti ci pan ts ge ne ral ly per fo rm at lea-
st one fun ctio nal assay (i.e., eit her VWF:R Co or 
VWF:CB) and in ~ 40% of ca ses per fo rm bo th as-
says. The CVs for all the se as say has been re por ted 
in the li te ra tu re and are de pen de nt on bo th the 
met ho do lo gy and le vel of VWF in the sam ple, but 
te nd to in crea se in the or der FVIII:C < VWF:Ag < 
VWF:CB < VWF:R Co, and CVs are hig he st when the 
VWF le vel is lowe st. In the mo re re ce nt re por ts, the 
is sue of diag nos tic in ter pre ti ve er ror ra tes as so cia-
ted wi th met ho do lo gy and te st pa ne ls has been 
explo red. The main fin di ng is that ad di tion of 
VWF:CB to a co re te st pa nel of FVIII:C, VWF:Ag, and 
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VWF:R Co wi ll con sis ten tly and sub stan tial ly re du ce 
VWD diag nos tic er ror ra tes.
Anot her ma jor re ce nt is sue explo red by the RCPA 
Hae ma to lo gy QAP was the eva lua tion of the per-
for man ce of the VWF tes ts at (diagnostically im-
por ta nt) low le ve ls of VWF (35). The RCPA QAP 
iden ti X ed the lower li mit of sen si ti vi ty for VWF:Ag 
and VWF:CB as says to be up to 10 U/dL, but this 
was up to 20 U/dL or grea ter for VWF:R Co. In te res-
tin gly, au to ma tion of ma ny of the se te st proce du-
res over the la st few yea rs has not im pro ved the 
lower li mit of sen si ti vi ty per for man ce in the diag-
nos tic hae mos ta sis la bo ra to ry. The RCPA Hae ma-
to lo gy QAP ma de se ve ral re com men da tio ns to he-
lp re du ce the pos si bi li ty of diag nos tic er ror in VWD 
re la ted to this is sue, and na me ly:
1. choo se ap prop ria te met ho do lo gies ca pab le of 
mea su ri ng le ve ls of VWF we ll be low 20 U/dL;
2. re peat VWF tes ti ng on a fre sh sam ple for con fir-
ma tion;
3. use a com pre hen si ve ran ge of ap prop ria te con-
tro ls;
4. ad ju st the con cen tra tion of the te st plas ma to 
mat ch as say to le ran ces; and
5. per fo rm as com pre hen si ve a te st pa nel as pos-
sib le.
Ot her EQA pro vi de rs ha ve re por ted on VWF tes ti-
ng, and ha ve al so shown con si de rab le va ria tion in 
te st prac ti ce and in te st re sul ts, bo th of whi ch 
com pro mi se the diag nos tic pro ce ss (79,80).
Pla te let fun ction tes ti ng
Al thou gh not ideal, re ce nt ini tia ti ves from the 
RCPA and ot her EQA pro vi de rs show that so me fo-
rm of EQA for pla te let fun ction tes ti ng is al so fea-
sib le (81–87). As an exam ple, the RCPA is o_ e ri ng a 
new prog ram to ca ter to the PFA-100 ana lysis in la-
bo ra to ries from 2010.
Gui de li nes for im pro vi ng the qua li ty of 
coa gu la tion and hae mos ta sis tes ti ng
A num ber of or ga ni za tio ns pro vi de gui de li nes to 
im pro ve the tes ti ng pro ce ss for coa gu la tion and 
hae mos ta sis. The se in clu de va rious ISTH SSCs, and 
CLSI. Thus, ISTH SSC gui de li nes for LA tes ti ng ha ve 
re cen tly been pub lis hed (43), as ha ve so me gui de-
li nes re la ted to pla te let fun ction tes ti ng usi ng the 
PFA-100 (88). The CLSI is al so ve ry ac ti ve in this are-
na, and has pub lis hed a wi de va rie ty of re le va nt 
gui de li nes, in clu di ng tho se for col lec tion and pro-
ces si ng of coa gu la tion sam ples (50), for ge ne ra ti ng 
nor mal re fe ren ce ran ges in tes ti ng (89), as we ll as 
for pla te let fun ction (52), VWF and fac tor tes ti ng 
(90; cur re ntly un der re vi sion), and PT and APTT tes-
ti ng (91). Ot her gui de li nes are in prog re ss, in clu di-
ng one on the Quan ti ta ti ve D-di mer for Exclu sion 
of Ve nous Throm boem bo li sm (cur ren tly in dra ft 
fo rm) and one on LA tes ti ng.
Con clu sion
The hae mos ta sis pat hway is very com plex, and in-
clu des va rious ele men ts of ac ti va tion and re gu la-
tion. The in ves ti ga tion of aber ra nt hae mos ta sis or 
the mo ni to ri ng of an ti coa gu la nt the ra py requi res 
the per for man ce of a mul ti tu de of te st pro ce du-
res. The se in tu rn can be in Z uen ced by ma ny fac-
to rs ran gi ng from an ti coa gu la nt the ra py, li ver di-
sea se, and in fec tio ns, in ad di tion to con ge ni tal 
and acqui red de fec ts. Spe ci X c pro ce du res for te st 
col lec tion, sam ple pre pa ra tion, te st per for man ce, 
and qua li ty as su ran ce need to be es tab lis hed in 
eve ry labo ra to ry to en su re pro vi sion of ac cu ra te 
and re liab le re sul ts to enab le ap prop ria te pa tie nt 
ma na ge me nt and ca re. IQC and EQA fa ci li ta te this 
pro ce ss to en su re the qua li ty of te st re sul ts. This is 
evi den ced by va rious exam ples wit hin this re view.
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Kva li te ta koa gu la cij skih pret ra ga i is pi ti va nja he mos ta ze
Sažetak
Ključni ele men ti prog ra ma proc je ne kva li te te, oso bi to unu tar nje kon tro le kva li te te (en gl. in ter nal qua li ty con trol, IQC) i vanj ske proc je ne kva li te te 
ra da (en gl. exter nal qua li ty as su ran ce, EQA) tre ba ju se prim je nji va ti u sva kom la bo ra to rij skom ispiti va nju, ka ko bi se osi gu ra la točno st i pre ciz no st 
na la za. Koa gu la cij ski la bo ra to rij ima važnu ulo gu u pos tav lja nju di jag no ze i li ječenju oso ba s po re mećaji ma kr va re nja ili zgrušava nja. Me to do lo-
gi je ana li za za proc je nu uo bičaje nih po re mećaja i bo les ti hemos ta ze oc je nju ju se is to kao i kli nički značaj sva ke ana li ze. U la bo ra to ri ju za he mos-
ta zu je pri jea na li tička fa za la bo ra to rij skog is pi ti va nja naj veći iz vor pog rešaka re zul ta ta, sto ga je na das ve važno is prav no sa ku pi ti, tran spor ti ra ti i 
poh ra ni ti uzor ke. Uzor ci za ana li zu he mos ta ze mo ra ju bi ti sa kup lje ni uz 3,2%-tni nat ri j-cit rat u om je ru kr vi i an ti koa gu lansa od 9:1 te se ti je kom 
ob ra de mo ra ju čuva ti na sob noj tem pe ra tu ri. Ne ki pos tup ci is pi ti va nja po put pret ra ge is pi ti va nja fun kci je trom bo ci ta sli je de po sebne zah tje ve za 
ob ra du i is pi ti va nje. Kod pret ra ga koje se od ređuju u plaz mi, cen tri fu gi ra nje za do bi va nje plaz me si ro mašne trom bo ci ti ma mo ra us li je di ti unu tar 
4 sa ta od uzi ma nja uzo ra ka ili se plaz ma mo ra zam r znu ti.
IQC se mo ra pro ves ti kod sva kog is pi tivanja na od go va ra jućoj ra zi ni ana li ta i u od go va ra jućim vre men skim raz ma ci ma kao sred stvo proc je ne is-
pi ti va nja u ti je ku. EQA, pro ces proc je ne pre ma sku pi ni me to da ko ji na do pu nju je IQC, do dat no nu di mo gućno st proc je ne du go ročnog ra da la bo-
ra to ri ja, uk ljučujući us po red be sa sličnim i raz ličitim me to do lo gi ja ma te čes to služi kao edu ka cij sko sred stvo. Sud je lo va nje u prog ra mu EQA čes to 
je je dan od zah tje va za ak re di ta ci ju la bo ra to ri ja. Pos to ji ve lik broj or ga ni za to ra međuna ro dnih prog ra ma EQA ko ji nu de po seb ne prog ra me za 
rutin ske i spe ci ja li zi ra ne tes to ve is pi ti va nja he mos ta ze. Ti prog ra mi da ju dra goc je nu in for ma ci ju o sto pi di jag nos tičkih pog rešaka za po je di ni te st, 
o pre ciz nos ti, točnos ti i os jet lji vos ti tes ta te proc je ni cje lo kup nog pro ce sa is pi ti va nja. Uk ljučiva nje IQC i EQA u la bo ra to rij ski prog ram neće sa mo 
po moći za ja mčiti pouz da no st i točno st is pi ti va nja, već će po bo ljšati i kva li te tu sa mog is pi ti va nja.
Ključne ri ječi: kva li te ta; he mos ta za; koa gu la ci ja; unu tar nja kon tro la kva li te te; vanj ska proc je na kva lite te rada
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